Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents

Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment

(2012) Hanne Fredly et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia

(2012) Tiphaine Adam de Beaumais et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL

(2012) M Leiva et al.   LEUKEMIA

Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells

(2012) Danian Nie et al.   LEUKEMIA & LYMPHOMA

Cross-Species Functional Genomic Analysis Identifies Resistance Genes of the Histone Deacetylase Inhibitor Valproic Acid

(2012) Rakel Brendsdal Forthun et al.   PLoS One

Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation

(2012) Karla Bennemann et al.   Clinical Epigenetics

The epigenetic effects of butyrate: potential therapeutic implications for clinical practice

(2012) Roberto Berni Canani et al.   Clinical Epigenetics

Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors

(2012) Geneviève P Delcuve et al.   Clinical Epigenetics

Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells

(2011) Ai-Hua Wang et al.   ANNALS OF HEMATOLOGY

Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

(2011) R. B. Walter et al.   HAEMATOLOGICA

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

(2011) E McCormack et al.   LEUKEMIA

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

(2011) A K Burnett et al.   LEUKEMIA

Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia hasin vitrobut limited clinical activity

(2011) Steven Lane et al.   LEUKEMIA & LYMPHOMA

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor

(2011) Wenjuan Yu et al.   LEUKEMIA RESEARCH

Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C

(2011) M.T. Corsetti et al.   LEUKEMIA RESEARCH

Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia

(2011) J Skavland et al.   Blood Cancer Journal

Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies

(2011) John Mascarenhas et al.   Clinical Epigenetics

Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

(2010) Myrna Candelaria et al.   ANNALS OF HEMATOLOGY

Epigenetics in AML

(2010) Ari M. Melnick   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

A novel effect of DNA methyltransferase and histone deacetylase inhibitors : NFκB inhibition in malignant myeloblasts

(2010) Claire Fabre et al.   CELL CYCLE

Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway

(2010) Jonathan R. St-Germain et al.   Epigenetics

Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells

(2010) Jie Chen et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

(2010) Thomas Prebet et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia – a report of five cases

(2010) Hanne Fredly et al.   Hematology

Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia

(2010) Liu-Fang Gu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia

(2010) A Quintás-Cardama et al.   LEUKEMIA

Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival

(2010) Lara Tickenbrock et al.   LEUKEMIA RESEARCH

Levels of Care: Defining Best Supportive Care in Elderly Patients with Acute Myeloid Leukemia

(2010) Ellen K. Ritchie et al.   Current Hematologic Malignancy Reports

Molecular marks for epigenetic identification of developmental and cancer stem cells

(2010) Samir Kumar Patra et al.   Clinical Epigenetics

Histone deacetylase inhibitors: clinical implications for hematological malignancies

(2010) Francesco Paolo Tambaro et al.   Clinical Epigenetics

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

(2010) Julia M. Wagner et al.   Clinical Epigenetics

Hydroxyurea and hydroxamic acid derivatives as antitumor drugs

(2009) Nina Saban et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis

(2009) Xuzhang Lu et al.   CANCER SCIENCE

Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes

(2009) S. Hauswald et al.   CLINICAL CANCER RESEARCH

Acute myelogenous leukemia

(2009) Joshua L. Shipley et al.   EXPERIMENTAL HEMATOLOGY

Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells

(2009) U. Langenkamp et al.   HAEMATOLOGICA

A phase 2 study of vorinostat in acute myeloid leukemia

(2009) E. W. Schaefer et al.   HAEMATOLOGICA

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

(2009) B ten Cate et al.   LEUKEMIA

Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate

(2009) A Poggi et al.   LEUKEMIA

Clinical correlation of circulating heat shock protein 70 in acute leukemia

(2009) Chen-Hsiung Yeh et al.   LEUKEMIA RESEARCH

Valproic acid exerts differential effects on CXCR4 expression in leukemic cells

(2009) Hilal Gul et al.   LEUKEMIA RESEARCH

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

ElevatedFOSB-expression; a potential marker of valproate sensitivity in AML

(2008) Farhat L. Khanim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

(2008) Gail J. Roboz et al.   CANCER

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

(2008) Pascale Flandrin et al.   CELL STRESS & CHAPERONES

Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia

(2008) Shabbir M.H. Alibhai et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Anticancer Immunotherapy in Combination with Proapoptotic Therapy

(2008) Oystein Bruserud et al.   CURRENT CANCER DRUG TARGETS

Demethylating agents in myeloid malignancies

(2008) Guillermo Garcia-Manero   CURRENT OPINION IN ONCOLOGY

Epigenetic therapy of leukemia: An update

(2008) Nitin Jain et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Retinoic acid syndrome: a review

(2008) E. Patatanian et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid

(2008) Anita Ryningen et al.   LEUKEMIA RESEARCH